Thank you for your continued interest in Wegovy® as we work toward resolving supply constraints following unprecedented product demand and short-term manufacturing issues. We expect to make all dose strengths of Wegovy® available in the US towards the end of the year.
From the outset, our top priority has been to support current patients who have started treatment with Wegovy® to be able to advance through dose escalation and stay on the maintenance dose. We took several steps as part of that commitment. We asked healthcare providers to not start new patients on Wegovy®, we have not advertised or promoted it and made the decision to temporarily stop shipments of the first two dose strengths (0.25 mg and 0.5 mg) — all to minimize demand from new patients and increase the likelihood there would be enough product available in the market to meet the needs of current people taking Wegovy®.
Our efforts to restore supply
We expect to make all dose strengths of Wegovy® available in the US towards the end of the year.
Commercial production at the contract manufacturing site was re-initiated and inventory building is ongoing. Novo Nordisk is also making plans for additional production capacity to come on-line in 2023.
We will ensure that we have all dose strengths of Wegovy® within our inventory before we support new patients being initiated and before we start other promotional efforts, consistent with our commitment to continuity of care.
We will continue to monitor the situation closely and will share timely and transparent updates and keep you informed on our progress.
For patients currently taking Wegovy® please know that some pharmacies may continue to experience normal Wegovy® product delays from time-to-time given supply variability. We encourage patients to contact their local pharmacy in advance to confirm that the pharmacy will be able to fill your prescription.
We apologize for any delay or disruption in treatment this situation may cause. If you have concerns, please contact your healthcare provider to determine the best approach for your treatment plan, in consideration of this supply situation.
We take our commitment to patients and the healthcare community very seriously and are doing everything we can to stabilize Wegovy® supply as quickly as possible. We believe the continued strong demand reflects the significant unmet medical need and the importance of this treatment option.
We appreciate your patience and understand your frustration. If you have concerns, we encourage you to speak to your healthcare provider about the weight management approach that is best for you.
We are here to help and are ready to answer your questions at 1-833-4-WEGOVY (1-833-493-4689) from 9 AM to 6 PM Eastern Monday through Friday – and select option 0 for more support.
If you have additional comments or would like to provide feedback on what other information would be helpful to you, please contact our Customer Care Center at 1-800-727-6500 or submit online. We will be reviewing that information on an ongoing basis and making periodic updates to this page. Please know that we take our responsibility to support you in this journey very seriously and are addressing this issue as a top priority. Thank you for your patience as we work to resolve this issue – which we will.